Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CIP-Tramadol Has April 2007 User Fee Date

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Cipher NDA submission for the sustained-release pain medication includes data from five Phase III studies.

You may also be interested in...



Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA

Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.

Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA

Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.

Cipher CIP-Tramadol ER Will Not Need Alcohol Interaction Study

Cipher no longer needs to complete a Phase I trial to investigate a potential interaction between the once-daily sustained-release pain medication CIP-tramadol ER and high levels of alcohol, the firm said June 15

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS064419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By